WO1999063058A1 - Milieu de culture de cellules animales et procede de production de proteines en utilisant ce milieu - Google Patents
Milieu de culture de cellules animales et procede de production de proteines en utilisant ce milieu Download PDFInfo
- Publication number
- WO1999063058A1 WO1999063058A1 PCT/JP1999/002904 JP9902904W WO9963058A1 WO 1999063058 A1 WO1999063058 A1 WO 1999063058A1 JP 9902904 W JP9902904 W JP 9902904W WO 9963058 A1 WO9963058 A1 WO 9963058A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fish meat
- medium
- cell culture
- culture medium
- animal cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
Definitions
- the present invention relates to an animal cell culture medium and a method for producing a protein using the same.
- the present invention relates to a medium for culturing animal cells and a method for producing a protein using the medium. Specifically, the present invention provides a medium for culturing animal cells containing a fish meat extract or an enzyme hydrolyzate of fish meat, and free of components such as proteins derived from mammals and their decomposition products, and a method for producing proteins using the same.
- a medium for culturing animal cells containing a fish meat extract or an enzyme hydrolyzate of fish meat, and free of components such as proteins derived from mammals and their decomposition products, and a method for producing proteins using the same.
- extracts for the propagation of the animal cells are usually derived from mammals, specifically serum such as fetal calf serum. Is added to the medium in the range of 5 to 20%.
- mammal-derived serum has the drawback that it occupies 75 to 95% of the cost of the medium, and that stable growth cannot be obtained due to differences in quality between lots.
- serum derived from mammals cannot be sterilized by autoclaving or the like, it may be contaminated with virus or mycoplasma, and although many of them are harmless, they are additional unknown factors in terms of stable production. sell.
- serum contains more than 500 proteins, which complicates the isolation and purification of the desired protein, a cell product from the culture medium.
- a method using a purified protein derived from serum such as fetuin, insulin, and transferrin instead of serum has been used.
- a method using a medium component extracted from a mammal has been attempted.
- mammal-derived components include mad cow disease, bovine spongiform encephalopathy (BSE), infectious spongiform encephalopathy (Transmissible Spongiform Encephalopathy: TSE), And Kreutsch There is concern about the relationship with Creutzfeld-Jakob Disease (CJD), etc., and the emergence of a culture medium for animal cells that does not contain these mammal-derived components is desired from the viewpoint of safety.
- BSE bovine spongiform encephalopathy
- TSE Transmissible Spongiform Encephalopathy
- CJD Creutzfeld-Jakob Disease
- An object of the present invention is to provide a medium for culturing animal cells that does not contain mammal-derived components without such a problem, and a method for producing protein using the medium. Disclosure of the invention
- the present inventors have developed a conventional medium for culturing animal cells using a CH0 cell transformed with a gene encoding an antibody protein, and excluding a component derived from a mammal from a conventional medium for animal cell culture.
- a fish meat extract or an enzyme hydrolyzate of fish meat was added. The inventor found that the intended purpose was achieved, and completed the present invention.
- the present invention relates to a medium for culturing animal cells containing a fish meat extract or an enzyme hydrolyzate of fish meat, and a method for producing a protein using the medium.
- Figure 1 is a graph showing the viable cell counts of CHO cells cultured in a medium containing 1% Brix and 2% Brix, and a medium containing 10 g / L of beef hydrolyzate.
- Fig. 2 is a graph showing the cell viability (%) of CHO cells cultured in a medium containing 1% Brix and 2% Brix, and a medium containing 10 g / L of beef hydrolyzate. is there.
- Figure 3 shows that CHO cells produced in a medium containing 1% Brix and 2% Brix containing enzyme digest of fish meat and a medium containing 10 g / L of beef hydrolyzate were produced in the medium. It is a graph which shows an antibody protein concentration (mg / L).
- FIG. 4 shows the results of cell culture using a shaker flask cell culture device in Example 5.
- the vertical axis indicates the number of living cells, cell viability, and the amount of antibody protein produced
- the horizontal axis indicates the number of days of culture since the start of culture using medium B.
- the medium of the present invention is a medium for culturing animal cells containing a fish meat extract or a fish meat enzyme digest. According to the present invention, animal cells can be satisfactorily cultured in a medium conventionally used as a medium for culturing animal cells without adding a component derived from a mammal.
- fish meat used in the present invention examples include fish meat such as red fish such as bonito, soda gallo, tuna, mackerel, sword fish, sardine, aji, salmon, and white fish such as fish, sea bream, sea bream, butterfly, sea bream, and the like. These are bonito, soda gallo, ⁇ , mackerel, salmon, and sardine.
- the fish meat extract used in the present invention may be prepared, for example, by cutting the above-mentioned fish meat into suitable fragments or mincing it into a paste, and solving the soluble component with hot water, for example, hot water at 90-95 ° C. It can be obtained by extracting from minutes to tens of hours. Specific examples include bonito broth during the production of bonito and cook drain during canning.
- the enzymatically decomposed product of fish meat is, for example, as follows: boiled fish meat as it is, or minced into a paste, or by adding an appropriate amount of water to the fish meat extract obtained as described above.
- the protein can be obtained by denaturing the protein by heating according to the above, treating with a protease, and removing the oil-insoluble material by centrifugation or filtration as appropriate.
- Such a fish meat extract or an enzymatically decomposed fish meat is preferably used after adjusting the pH to about 7 to 7.4.
- the proteolytic enzymes used in the present invention include proteinases and / or beptidases.
- proteinase refers to an enzyme that hydrolyzes proteins based on protein
- peptidase refers to peptide bond hydrolases using peptides as substrates. That is, the protease tan
- the activity on protein substrates can be distinguished as proteinase activity, and the activity on peptide substrates can be distinguished as beptidase activity.
- proteinase is used to catalyze the cleavage of peptide bonds from the middle due to their activity on protein substrates, and thus endopeptidases are used herein as one type of proteinase. I have.
- enzyme of plant origin such as papain, chymopapain, promelain, and fusin
- an enzyme of microbial origin such as mold, bacteria, and yeast, such as endopeptidase, exopeptidase, and aminopeptidase.
- enzymes such as carboxypeptidase and dipeptidase.
- an enzyme digest of fish meat obtained by treating with the above proteinase and then with beptidase is preferable.
- the enzymatic treatment depends on the type of enzyme used, but is usually pH2-12, preferably pH4_8, at a temperature of 30-90 ° C, preferably 40-65 ° C, for 30 minutes-72 hours. Best practice is 3-24 hours. At this time, the enzyme is used in an amount of 0.01-10%, preferably 0.5-5%, more preferably 1-3% of the protein as a substrate.
- the enzymatic hydrolyzate After deactivating the enzyme in the enzymatic hydrolyzate of the fish meat obtained in this way by heating, etc., the enzymatic hydrolyzate is prepared by removing the oil and insolubilized substances by appropriate centrifugation and filtration. can do.
- each component usually used in animal cell culture medium can be appropriately used, and these include amino acids, vitamins, lipid factors, energy sources, osmotic pressure regulators, iron Source, including pH buffer.
- these components for example, a trace metal element, a surfactant, a growth auxiliary factor, a nucleoside, and the like may be added.
- L-alanine, L-arginine, L-asparagine, L-asparaginate, L-cystine, L-cystine, L-glutamine, L-glutamic acid glycine, L-histidine, L-histamine Isoleucine, L-leucine, L-lysine, L-methionine, L-orditin, L-phenylalanine, L-proline, L-serine, L-threonine, L-tributofan, L-tyrosine, L-valine Etc., preferably L-alanine, L-arginine, L-asparagine, L-asparaginate, L-cystine, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine L-proline, L
- Osmolarity adjusting agents such as sodium chloride; iron EDTA, iron citrate, ferrous chloride, ferric chloride, ferrous sulfate, ferric sulfate, ferric nitrate, etc., preferably salts
- Iron sources such as ferric ferric iron, EDTA iron and iron citrate
- pH buffers such as sodium bicarbonate, sodium salt calcium, sodium dihydrogen phosphate, HEPES, MOPS, and preferably sodium hydrogen carbonate
- Examples of the medium include
- trace metals such as copper sulfate, manganese sulfate, zinc sulfate, magnesium sulfate, nickel chloride, tin chloride, magnesium chloride, sodium silicate, and the like, preferably copper sulfate, zinc sulfate, and magnesium sulfate elements; Twee n 80, surfactants such as pull port nick F68; and recombinant insulin, recombinant IGF, recombinant EGF, recombinant FGF, recombinant PDGF, recombinant TGF-a, hydrochloride Ethano-Alumina, sodium selenite, retinoic acid, butrethine hydrochloride, etc., preferably, growth-promoting factors such as sodium selenite, ethanolamine hydrochloride, recombinant IGF, butrethine hydrochloride, etc .; deoxyadenosine, deoxycytidine
- antibiotics such as streptomycin, penicillin G potassium and gentamicin, and pH indicators such as phenol red may be contained.
- a commercially available medium for culturing animal cells for example,
- a medium such as a BME medium, a MEM medium, a DMEM medium, an F10 medium, or an F12 medium may be prepared by adding a fish meat extract or an enzyme hydrolyzate of fish meat instead of a component derived from a mammal. .
- a fish meat extract or an enzyme hydrolyzate of fish meat is added to the medium so that the concentration of Brix is 5% or less, preferably 0.5 to 3% of Brix, and particularly preferably about 1 to 2% of Brix in the medium.
- concentration is a concentration using soluble solids measured by a refractometer as an index.
- the content of other components in the culture medium was 0.05-1500 mg / L for amino acids, 0.001-10 mg / L for bisamines, 0-200 mg / L for lipid factors, and 1-120 g / L for energy sources.
- Osmotic pressure regulator is 0.1-10000mg / L
- iron source is 0.1-500mg / L
- pH buffer is 1-10000mg / L
- trace metal element is 0.00001-200mg / L
- surfactant is 0-5000mg / L.
- the growth co-factor ranges from 0.05 to 10000 g / L and the nucleoside ranges from 0.001 to 50 mg / L, and can be determined as appropriate depending on the type of animal cells to be cultured, the type of desired protein, and the like.
- the pH of the medium depends on the cells to be cultured, but is generally pH 6.8 to 7.6, and in many cases pH 7.2 to 7.4.
- the medium of the present invention can be used for suitably culturing various animal cells without any particular limitation.
- the resulting fused cells can be cultured. Particularly, it is suitable for culturing CHO cells.
- the medium for culturing animal cells of the present invention can also be used when culturing animal cells to obtain a natural protein produced by the animal cells. It can also be used for culturing eLa cells and the like.
- culture conditions vary depending on the type of cells used, appropriate conditions may be determined as appropriate.
- C0 2 concentration of 0 40% of the gas phase rather preferably has an atmosphere 2- 10%, 30- 39:, preferably at about 37 ° C, 1-14 It should be cultivated for days.
- various culture devices for culturing animal cells include a fermenter tank culture device, an air lift culture device, a culture flask culture device, a spinner flask culture device, a microcarrier culture device, and a fluidized bed culture device.
- the culture can be performed using a device, a Holof-Iver type culture device, a roller bottle type culture device, a filling tank type culture device, or the like.
- proteins produced by animal cells can be obtained in the medium.
- the production of protein from animal cells includes those that only require culturing the protein and those that require special operations. These operations or conditions may be appropriately determined depending on the animal cells to be cultured. For example, in a CHO cell transformed by a vector containing a gene encoding a mouse-human chimeric antibody by genetic engineering, culturing under the above-described conditions is preferable for 114 days. Can obtain the desired protein in the medium in about 7 to 10 days.
- Recombinant antibodies such as anti-human IL-6 receptor antibody, granulocyte colony stimulating factor (G-CSF), granulocytes Genetically modified proteins such as macrophage colony stimulating factor (GM-CSF), erythropoietin, inuichiferon, interleukins such as IL-1 and IL-6, t-PA, perokinase, serum albumin, and blood coagulation factor I Can be manufactured.
- the medium for culturing animal cells according to the present invention contains a fish meat extract or an enzyme hydrolyzate of fish meat, so that animal cells can be stably used without using expensive and highly variable proteins such as fetal bovine serum. Can be cultured. Furthermore, by culturing animal cells in a cell culture medium containing the fish meat extract or the enzyme digest of fish meat of the present invention, contamination by abnormal prions or viruses, which have recently become a problem, can be prevented. The danger has been eliminated and safe biopharmaceuticals can be manufactured and provided.
- a medium obtained by removing thymidine and hypoxanthine from a commercially available DMEM / F12 medium (GIBCO BRL Products and Reference Guide, p.357-358) and adding the following components (hereinafter In this case, the medium A was used).
- Example 4 Effect on antibody production
- U.S. Patent Application Publication No. US Pat. No. 5,049,086 discloses the use of the humanelongation factor I promoter described in Example 10 of International Patent Application Publication No.
- the test was performed using a CHO cell line that produces a humanized PM-1 antibody (anti-human IL-16 receptor antibody) prepared according to the method described in Reference Example 2.
- the above-mentioned CHO cells (1.5xl0 5 cell / ml) were added to the medium A containing the final concentration of Brix 1% or Brix 2% with the enzyme digest of fish meat prepared in Example 2 of the present specification.
- the cells were cultured for 10 days under the incubator conditions of 37 ° C. and 5% CO 2 using a cell culture device.
- the production was measured using reversed-phase high performance liquid chromatography.
- a medium containing 10 g / L of beef hydrolyzate (Primatone TM: manufactured by Quest, USA) was prepared in place of the enzyme hydrolyzate of Example 2, and CHO cells were cultured in the same manner. The results obtained are shown in FIG. Compared to the control, CHO cells cultured in a medium containing Brixl% of the enzyme digest of bonito showed cell growth equivalent to the control. In addition, CHO cells cultured in a medium containing 2% Brix, an enzyme hydrolyzate of bonito, produced more antibody protein than control.
- Example 5 Effect of medium using various enzyme digests of fish meat on antibody production Amount of enzyme digest of fish meat using bonito, sardine, salmon, soda katsuo, ⁇ , and mackerel as raw materials was converted to a non-mammalian animal-derived medium. The amount of antibody protein produced was examined by the addition.
- An enzyme digest of fish meat was prepared using the method described in Example 2. That is, fish meat was cut into minced fish, and enzyme digestion was performed with papain, which is a plant-derived endopeptidase. Next, the enzyme was further decomposed with mold-derived exopeptidase and heated to inactivate the enzyme. Insoluble matter and oil were removed by centrifugation and filtration, and concentrated to prepare enzymatically decomposed fish meat.
- the dhfr (1) CHO cells transformed with the gene encoding the humanized PM-1 antibody (anti-human IL-16 receptor antibody) protein and the dhfr selection marker gene described in Example 4 were subjected to bonito and sardine.
- Salmon, soda katsuo, ⁇ , and mackerel are added to medium B containing a final concentration of 10 g / L (Brix 1%) or 15 g / L (Brix 1.5%), and the mixture is shaken using a shaker flask cell culture device. ° C, and cultured for 10 days in 5% C0 2 incubator conditions. The viable cell count, cell viability, and antibody protein production were measured.
- the components of medium B are shown below.
- Fig. 4 shows the obtained results.
- the final concentration of enzymatic hydrolyzate of fish meat is 1% Brix (I0g / L)
- the sequence of bonito> soudagasso> ⁇ > salmon> mackerel> sardine is in descending order of production.
- the final concentration of the enzyme digest of fish meat is 1.5% Brix (I5g / L) added, then bonito> soda gallo> ⁇ > mackerel> salmon> sardine.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/701,518 US6537782B1 (en) | 1998-06-01 | 1999-01-01 | Media for culturing animal cells and process for producing protein by using the same |
DE69935978T DE69935978T2 (de) | 1998-06-01 | 1999-06-01 | Kulturmedium zur Kultivierung tierischer Zellen und Verfahren zur Herstellung von Proteinen durch dessen Verwendung |
JP2000552254A JP3510858B2 (ja) | 1998-06-01 | 1999-06-01 | 動物細胞培養用培地およびそれを使用してタンパク質を製造する方法 |
CA002333966A CA2333966C (en) | 1998-06-01 | 1999-06-01 | Media for culturing animal cells and process for producing protein by using the same |
AU39584/99A AU744715B2 (en) | 1998-06-01 | 1999-06-01 | Culture medium for culture of animal cell and method for producing protein using same |
IL13997499A IL139974A (en) | 1998-06-01 | 1999-06-01 | Culture medium for culture of animal cell and method for producing protein using same |
EP99922611A EP1085083B1 (en) | 1998-06-01 | 1999-06-01 | Culture medium for culturing of animal cells and method for producing proteins using the same |
DK99922611T DK1085083T3 (da) | 1998-06-01 | 1999-06-01 | Dyrkningsmedium for dyreceller og fremgangsmåde til proteinfremstilling under anvendelse af dette |
NO20006096A NO326180B1 (no) | 1998-06-01 | 2000-11-30 | Medium for dyrking av dyreceller og fremgangsmate for fremstilling av protein ved anvendelse av de samme |
HK01108662A HK1037678A1 (en) | 1998-06-01 | 2001-12-10 | Media for culturing animal cells and process for producing protein by using the same. |
US10/336,825 US6962812B2 (en) | 1998-06-01 | 2003-01-06 | Culture medium for culture of animal cell and method for producing protein using same |
NO2009012C NO2009012I1 (no) | 1998-06-01 | 2009-05-28 | Humanisert anti-humant IL-6 reseptor monoklonalt antistoff |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/150957 | 1998-06-01 | ||
JP15095798 | 1998-06-01 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/701,518 A-371-Of-International US6537782B1 (en) | 1998-06-01 | 1999-01-01 | Media for culturing animal cells and process for producing protein by using the same |
US09701518 A-371-Of-International | 1999-06-01 | ||
US10/336,825 Division US6962812B2 (en) | 1998-06-01 | 2003-01-06 | Culture medium for culture of animal cell and method for producing protein using same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999063058A1 true WO1999063058A1 (fr) | 1999-12-09 |
Family
ID=15508136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/002904 WO1999063058A1 (fr) | 1998-06-01 | 1999-06-01 | Milieu de culture de cellules animales et procede de production de proteines en utilisant ce milieu |
Country Status (16)
Country | Link |
---|---|
US (2) | US6537782B1 (ja) |
EP (1) | EP1085083B1 (ja) |
JP (1) | JP3510858B2 (ja) |
KR (1) | KR100430447B1 (ja) |
CN (1) | CN1187441C (ja) |
AT (1) | ATE361360T1 (ja) |
AU (1) | AU744715B2 (ja) |
CA (1) | CA2333966C (ja) |
DE (1) | DE69935978T2 (ja) |
DK (1) | DK1085083T3 (ja) |
ES (1) | ES2285840T3 (ja) |
HK (1) | HK1037678A1 (ja) |
IL (1) | IL139974A (ja) |
NO (2) | NO326180B1 (ja) |
RU (2) | RU2214455C2 (ja) |
WO (1) | WO1999063058A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006073070A1 (ja) | 2005-01-05 | 2006-07-13 | Chugai Seiyaku Kabushiki Kaisha | 細胞の培養方法およびその利用 |
KR20230124607A (ko) | 2020-12-22 | 2023-08-25 | 가부시키가이샤 마루하치 무라마쓰 | 펩타이드, 세포 증식 촉진제, 단백질 산생 촉진제,배지, 그 펩타이드를 이용한 세포 증식 방법, 및, 그 펩타이드를 이용한 단백질 산생 방법 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2312184T3 (es) | 1997-03-21 | 2009-02-16 | Chugai Seiyaku Kabushiki Kaisha | Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas. |
CA2395271A1 (en) * | 1999-12-28 | 2001-07-05 | Isotis N.V. | Cell culture medium containing growth factors and l-glutamine |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
DE10124820A1 (de) | 2001-05-21 | 2002-12-05 | Heinrich Wieland | Zusammensetzung und Verwendung von Substanzen zur Stabilisierung von schwefelhaltigen Aminosäuren im Blut |
EP2311489A3 (en) | 2002-02-14 | 2013-08-21 | Chugai Seiyaku Kabushiki Kaisha | Formulation of antibody-containing solutions comprising a sugar as a stabilizer |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
WO2005090405A1 (ja) | 2004-03-24 | 2005-09-29 | Chugai Seiyaku Kabushiki Kaisha | インターロイキン-6受容体に対するヒト型化抗体のサブタイプ |
US20060094104A1 (en) * | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
KR100679112B1 (ko) * | 2004-11-17 | 2007-02-07 | 삼성정밀화학 주식회사 | 동물세포 배양방법 |
WO2007070315A2 (en) | 2005-12-08 | 2007-06-21 | Amgen Inc. | Improved production of glycoproteins using manganese |
ES2474573T3 (es) * | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
JP5711751B2 (ja) | 2009-10-26 | 2015-05-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | グリコシル化された免疫グロブリンの調製方法 |
MD191Z5 (ro) * | 2010-01-21 | 2010-11-30 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Mediu nutritiv pentru cultivarea celulelor de origine animală |
MX2013005024A (es) | 2010-11-08 | 2013-11-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-il-6 receptor administrado subcutaneamente. |
CA2913687C (en) | 2013-07-04 | 2022-12-13 | F. Hoffmann-La Roche Ag | Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples |
CA2928726A1 (en) | 2013-10-30 | 2015-05-07 | The Curators Of The University Of Missouri | Method for scalable skeletal muscle lineage specification and cultivation |
KR20180009760A (ko) | 2015-05-27 | 2018-01-29 | 아스테라스 세이야쿠 가부시키가이샤 | 핵산 함유 배지를 이용한 세포 배양 방법 |
WO2017147169A1 (en) | 2016-02-22 | 2017-08-31 | Ohio State Innovation Foundation | Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites |
WO2018170405A1 (en) | 2017-03-17 | 2018-09-20 | Ohio State Innovation Foundation | Nanoparticles for delivery of chemopreventive agents |
US11976302B2 (en) | 2017-05-06 | 2024-05-07 | Upside Foods, Inc. | Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure |
WO2019014652A1 (en) | 2017-07-13 | 2019-01-17 | Memphis Meats, Inc. | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CELL CULTURES USED IN FOOD PRODUCTION |
JP2022527972A (ja) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4954581A (ja) * | 1972-09-13 | 1974-05-27 | ||
JPH01148181A (ja) * | 1987-12-07 | 1989-06-09 | Jgc Corp | グルタチオンの菌体内蓄積法 |
JPH0239882A (ja) * | 1988-07-29 | 1990-02-08 | Japan Synthetic Rubber Co Ltd | 動物細胞培養用培地 |
JPH0638704A (ja) * | 1991-06-19 | 1994-02-15 | Morinaga Milk Ind Co Ltd | 発酵調味料及びその製造法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3962425A (en) * | 1972-09-21 | 1976-06-08 | Weyerhaeuser Company | Ruminant repellent from enzymatically putrefied lipoidal material |
JPS5336033B2 (ja) * | 1972-12-11 | 1978-09-30 | ||
US5426045A (en) | 1993-12-16 | 1995-06-20 | Sea Run Holdings, Inc. | Method for culturing mammalian cells in a medium containing fish serum |
WO1995023212A1 (en) | 1994-02-23 | 1995-08-31 | Sea Run Holdings, Inc. | Method for culturing mammalian cells and insect cells in a medium containing fish serum |
CN1157694A (zh) | 1996-10-15 | 1997-08-27 | 玉环县海天营养源有限公司 | 一种液化鱼蛋白粉的制作方法 |
-
1999
- 1999-01-01 US US09/701,518 patent/US6537782B1/en not_active Expired - Lifetime
- 1999-06-01 IL IL13997499A patent/IL139974A/xx not_active IP Right Cessation
- 1999-06-01 CA CA002333966A patent/CA2333966C/en not_active Expired - Lifetime
- 1999-06-01 RU RU2000133243/13A patent/RU2214455C2/ru active
- 1999-06-01 JP JP2000552254A patent/JP3510858B2/ja not_active Expired - Lifetime
- 1999-06-01 CN CNB998085766A patent/CN1187441C/zh not_active Expired - Lifetime
- 1999-06-01 DK DK99922611T patent/DK1085083T3/da active
- 1999-06-01 WO PCT/JP1999/002904 patent/WO1999063058A1/ja active IP Right Grant
- 1999-06-01 DE DE69935978T patent/DE69935978T2/de not_active Expired - Lifetime
- 1999-06-01 EP EP99922611A patent/EP1085083B1/en not_active Expired - Lifetime
- 1999-06-01 ES ES99922611T patent/ES2285840T3/es not_active Expired - Lifetime
- 1999-06-01 AU AU39584/99A patent/AU744715B2/en not_active Expired
- 1999-06-01 KR KR10-2000-7013548A patent/KR100430447B1/ko active Protection Beyond IP Right Term
- 1999-06-01 RU RU2003113779/13A patent/RU2333242C2/ru active
- 1999-06-01 AT AT99922611T patent/ATE361360T1/de active
-
2000
- 2000-11-30 NO NO20006096A patent/NO326180B1/no not_active IP Right Cessation
-
2001
- 2001-12-10 HK HK01108662A patent/HK1037678A1/xx unknown
-
2003
- 2003-01-06 US US10/336,825 patent/US6962812B2/en not_active Expired - Lifetime
-
2009
- 2009-05-28 NO NO2009012C patent/NO2009012I1/no not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4954581A (ja) * | 1972-09-13 | 1974-05-27 | ||
JPH01148181A (ja) * | 1987-12-07 | 1989-06-09 | Jgc Corp | グルタチオンの菌体内蓄積法 |
JPH0239882A (ja) * | 1988-07-29 | 1990-02-08 | Japan Synthetic Rubber Co Ltd | 動物細胞培養用培地 |
JPH0638704A (ja) * | 1991-06-19 | 1994-02-15 | Morinaga Milk Ind Co Ltd | 発酵調味料及びその製造法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006073070A1 (ja) | 2005-01-05 | 2006-07-13 | Chugai Seiyaku Kabushiki Kaisha | 細胞の培養方法およびその利用 |
JP4818936B2 (ja) * | 2005-01-05 | 2011-11-16 | 中外製薬株式会社 | 細胞の培養方法およびその利用 |
EP2843040A1 (en) | 2005-01-05 | 2015-03-04 | Chugai Seiyaku Kabushiki Kaisha | Cell culture method and utilization of the same |
US9714410B2 (en) | 2005-01-05 | 2017-07-25 | Chugai Seiyaku Kabushiki Kaisha | Cell culture method and utilization of the same |
KR20230124607A (ko) | 2020-12-22 | 2023-08-25 | 가부시키가이샤 마루하치 무라마쓰 | 펩타이드, 세포 증식 촉진제, 단백질 산생 촉진제,배지, 그 펩타이드를 이용한 세포 증식 방법, 및, 그 펩타이드를 이용한 단백질 산생 방법 |
Also Published As
Publication number | Publication date |
---|---|
ES2285840T3 (es) | 2007-11-16 |
NO20006096L (no) | 2001-02-01 |
DE69935978T2 (de) | 2008-01-17 |
NO2009012I1 (no) | 2009-06-15 |
CN1309698A (zh) | 2001-08-22 |
AU3958499A (en) | 1999-12-20 |
US6537782B1 (en) | 2003-03-25 |
EP1085083B1 (en) | 2007-05-02 |
RU2333242C2 (ru) | 2008-09-10 |
CN1187441C (zh) | 2005-02-02 |
CA2333966C (en) | 2006-07-25 |
US6962812B2 (en) | 2005-11-08 |
DK1085083T3 (da) | 2007-06-18 |
HK1037678A1 (en) | 2002-02-15 |
AU744715B2 (en) | 2002-02-28 |
KR20010071359A (ko) | 2001-07-28 |
KR100430447B1 (ko) | 2004-05-10 |
CA2333966A1 (en) | 1999-12-09 |
US20030096372A1 (en) | 2003-05-22 |
ATE361360T1 (de) | 2007-05-15 |
NO20006096D0 (no) | 2000-11-30 |
EP1085083A1 (en) | 2001-03-21 |
IL139974A0 (en) | 2002-02-10 |
AU744715C (en) | 1999-12-20 |
DE69935978D1 (de) | 2007-06-14 |
NO326180B1 (no) | 2008-10-13 |
IL139974A (en) | 2005-09-25 |
JP3510858B2 (ja) | 2004-03-29 |
EP1085083A4 (en) | 2002-11-27 |
RU2214455C2 (ru) | 2003-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999063058A1 (fr) | Milieu de culture de cellules animales et procede de production de proteines en utilisant ce milieu | |
TWI409332B (zh) | 細胞之培養方法及其利用 | |
KR102109463B1 (ko) | 소형 펩티드를 포함하는 세포 배양 배지 | |
WO2000003000A2 (en) | Serum-free medium for culturing animal cells | |
JP3822137B2 (ja) | 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法 | |
JPWO2016153041A1 (ja) | 銅イオン制御製造方法 | |
JPH09512171A (ja) | 無血清培地添加物 | |
JP3950834B2 (ja) | 動物細胞培養用培地およびそれを使用してタンパク質を製造する方法 | |
JP2850430B2 (ja) | 細胞培養用無血清培地 | |
JPH03201981A (ja) | 細胞培養用無血清培地の調製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99808576.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 139974 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2333966 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09701518 Country of ref document: US Ref document number: 1020007013548 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 39584/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999922611 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999922611 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007013548 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 39584/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007013548 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999922611 Country of ref document: EP |